Characteristics

LMR < 2.8 (n = 42)

LMR≥ 2.8 (n = 97)

P value

Age (years)

<60

≥60

28 (66.7%)

14 (33.3%)

78 (80.4%)

19 (19.6%)

0.08

Sex

Male

Female

26 (61.9%)

16 (38.1%)

56 (57.7%)

41 (42.3%)

0.64

ECOG PS

0

1

2

6 (14.3%)

24 (57.1%)

12 (28.6%)

34 (35.%1)

50 (51.5%)

13 (13.4%)

0.01

Extra-nodal sites

>1

≤1

10 (23.8%)

32 (76.2%)

53 (54.6%)

44 (45.4%)

0.001*

Ann Arbor stage

I

II

III

IV

1 (2.4%)

7 (16.7%)

23 (54%.8)

11 (26.2%)

3 (3.1 %)

34 (35.1%)

40 (41.2%)

20 (20.6%)

0.086

IPI

0

1

2

3

4

5

1 (2.4%)

1 (2.4%)

11 (26.2%)

21 (50%)

7 (16.7%)

1 (2.4%)

14 (14.4%)

19 (19.6%)

29 (29.9%)

34 (35.1%)

1 (1%)

0 (0.0%)

<0.001*

Treatment

R-CHOP

CHOP

4 (9.5%)

38 (90.5%)

31 (32%)

66 (68%)

0.005

Following completion of therapy

ALC

AMC

1025 (770 - 1430)

490 (280 - 680)

1320 (1100 - 1870)

310 (200 - 650)

<0.001*

<0.001*

Following completion of therapy LDH

Normal

>Normal

16 (38.1%)

26 (61.9%)

75 (77.3%)

22 (22.7%)

<0.001*

State of disease

Follow up

Relapsed

5 (11.9%)

37 (88.1%)

95 (97.9%)

2 (2.1%)

<0.001*